Home IPO candidate Atara shifts in deal with Memorial Sloan Kettering
 

Keywords :   


IPO candidate Atara shifts in deal with Memorial Sloan Kettering

2014-09-24 04:26:07| Biotech - Topix.net

Isaac Ciechanover's Atara Biotherapeutics has an option to license three experimental drug programs from Memorial Sloan Kettering Cancer Center. IPO-ready Atara Biotherapeutics could license from Memorial Sloan Kettering Cancer Center three treatments already in human clinical trials for certain cancers and persistent viral infections, the company said Tuesday.

Tags: deal candidate memorial ipo

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.07Tropical Storm Beryl Public Advisory Number 33
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Tropical Storm Beryl Public Advisory Number 32A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Eastern North Pacific Tropical Weather Outlook
06.07Atlantic Tropical Weather Outlook
06.07Axalta Schedules Second-Quarter 2024 Earnings Conference Call
06.07Tropical Storm Beryl Potential Storm Surge Flooding Map
More »